Anti-VEGF therapy in a specialized budgetary institution (by the data of Penza Regional Eye Hospital)
S.L. KUZNETSOV1, R.S. GALEYEV2, F.A. ANESYAN3, E.E. BRAZHALOVICH1, K.A. VYAZOVKINA3, D.D. MAKAROVA3
1Penza Institute for Advanced Medical Education ― Branch Campus of the FSBEI FPE RMACPE MOH Russia, 8a Stasov Str., Penza, Russian Federation, 440062
2Penza Regional Eye Hospital, 32 Krasnaya Str., Penza, Russian Federation, 440026
3Medical Institute of Penza State University, 40 Krasnaya Str., Penza, Russian Federation, 440026
Contact:
Kuznetsov S.L. ― Cand. Med. Sc., Associate Professor, Head of the Ophthalmology Department, e-mail: slkclinic@gmail.com
Galeyev R.S. ― Cand. Med. Sc., Chief Doctor, tel. (8412) 32-03-33, e-mail: semash@e-pen.ru
Anesyan F.A. ― resident of the Ophthalmology Course at the Maxillofacial Surgery Department, e-mail: anesyan@mail.ru
Brazhalovich E.E. ― Senior laboratory assistant of the Ophthalmology Department, e-mail: alena29216@mail.ru
Vyazovkina K.A. ― resident of the Ophthalmology Course at the Maxillofacial Surgery Department, e-mail: oksa996@bk.ru
Makarova D.D. ― student of the Therapy Faculty, e-mail: lanaivanova1990@gmail.com
The article presents the results of structural analysis of anti-VEGF therapy during 4 years by the data of budgetary healthcare institution (Penza Regional Eye Hospital). For the period from February 24, 2014 to November 23, 2017, a systematic quantitative analysis was performed using retrospective non-continuous monographic observation and calculation of generalized indicators and the mean index for all cases of anti-VEGF therapy with ranibizumab and aflibercept in 774 patients (961 eyes) with diagnoses: age-related macular degeneration, wet form (AMD); postthrombotic retinopathy with macular edema (PTR); proliferative diabetic retinopathy (PDR); high complicated myopia with maculopathy and neovascularization (HCM). It was found that 63.79% of the eyes were once injected with an anti-VEGF preparation, another 21.02% had 2 injections, and 15.18% of the eyes received 3 or more injections of anti-VEGF drugs. In the eyes with AMD, 1-2 injections were made in 82.44% of cases, and 3 or more ― in 17.56%; in the eyes with PTR, respectively, in 90.08% and 9.92%, in the eyes with PDR ― in 88.94% and 15.06% and the eyes with HCM ― in 82.36% and 17.64% respectively. The index of drugs injections per eye was, on average, 1.65, and the maximum was 1.7. During 2014-2016, an increase in the injection index was observed, both for all patients (from 1.56 to 1.93) and for particular diseases. The main problem is finding the optimal balance between «new to this therapy» patients and those who need to continue therapy and follow the protocols of drug administration under anti-VEGF medication deficit.
Key words: anti-VEGF therapy, injection index, ranibizumab, aflibercept.
REFERENCES
- Podgornaya N.N. Current treatment options for age-related macular degeneration of the retina. Klinicheskaya gerontologia, 2015, vol. 21, no 1-2, pp. 48-53. (In Russ).
- Dhoot D.S., Kaiser P.K. Ranibizumab for age-related macular degeneration. Opin. Biol. Ther., 2012, vol. 12, no 3, pp. 371-381.
- Patel R.D., Momi R.S., Hariprasad S.M. Review of ranibizumab trials for neovascular age-related macular degeneration. Ophthalmol., 2011, vol. 26, no 6, pp. 372-379.
- Shadrichev F.E., Grigoryeva N.N., Shklyarov E.B. Diabetic macular edema. What can modern ophthalmology offer? Rossiyskiy Oftalmologicheskiy Zhurnal, 2015, vol. 8, no 4, pp. 88-94. (In Russ.).
- Astakhov Yu.S., Nechiporenko P.A. Treatment with aflibercept in patients with diabetic macular edema. Oftalmologicheskie Vedomosti, 2017, vol. 10, no 2, pp. 94-109. (In Russ.).
- Alpatov S.A. Blockers of angiogenesis in the treatment of eye diseases. Klinicheskaya Oftalmologia, 2015, no 4, pp. 196-200. (In Russ.).
- Vora R.A. Book Review: Anti-VEGF Use in Ophthalmology. J. Retina Vitreous, 2017, no 3, pp. 35.
- Duker J.S., Liang M.C. Anti-VEGF Use in Ophthalmology, 2017, 200 p.
- Top 25 Innovations in Eye Care of the Last 25 Years: Special content developed from survey data collected from the audiences of Ophthalmology Times and Ophthalmology Times Europe. Available at: http://www.modernmedicine.com/tag/top-25-eye-care-innovations.
- Aksyonova S.V., Kulikova M.P., Sedoykina A.V. The experience of using Lucentis in the treatment of a moist form of age-related macular degeneration. Nauchnyi Almanakh, 2015, no 10-3 (12), pp. 300-303. (In Russ.).
- Seleznyov A.V., Nagornova Z.M. Modern approach to the treatment of retinal vein occlusions. Vestnik Ivanovskoy Medicinskoy Akademii, 2016, vol. 21, no 3, pp. 49-53. (In Russ.).
- Zavgorodnyaya N.G., Poplavskaya I.A., Shevlyuk S.L., Martynov D.V. Analysis of the intravitreal administration of anti-VEGF preparations in diseases of the fundus accompanied by exudation and neovascularization. Patologia, 2013, no 2 (28), pp. 49-52. (In Russ.).
- Velichko P.B. Complex treatment of diabetic macular edema. Vestnik Tambovskogo Universiteta. Seriya: Estestvennye i tekhnicheskie nauki, 2014, vol. 19, no 4, pp. 1097-1101. (In Russ.).
- Shambra S.V., Fedchenko S.A., Ryabchun O. V. et al. Antiangiogenic therapy of age-related degeneration of the macula. Оftalmologicheskiy zhurnal, 2015, no 3(494), pp. 93-100. (In Russ).
- Danilova L.P., Egorov V.V., Smolyakova G.P. et al. Results of application of anti-VEGF preparation in choroidal neovascularization in patients with degenerative myopia. Oftalmologia, 2016, vol. 13, no 3, pp. 184-190. (In Russ).
- Budzinskaya M.V., Zhabina О.А., Andreeva I.V., Plukhova А.А. The effectiveness of anti-VEGF therapy in patients with choroidal neovascularization in the background of myopic maculopathy. Tochka zreniya. Vostok – Zapad, 2015, no 1, pp. 136-137. (In Russ).
- Bratko G.V., Smirnov Е.V., Trunov А.N., Chernykh V.V. The practice of applying anti-VEGF therapy in Russia: the results of an online survey. Sovremennye tekhnologii v oftalmologii, 2015, no 1, pp. 39-41. (In Russ).
- Wells J.A. A Deeper Look at Protocols S and T. Review of Ophthalmology, 2016, October 5. – Available at: https://www.reviewofophthalmology.com/article/a-deeper-look-at-protocols-s-and-t
- Goodall K., Levy A. Real-world strategies for wet AMD. Ophthalmology Times: Europe. – 2016, February 29. – Available at: http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/real-world-strategies-wet-amd